Mergers & acquisitions – it’s all about collaboration, says Mike Straw, Achieve Breakthrough. He argues that deals are all about people as well as the numbers – and it’s the collaboration that will make a deal truly work.
The international, niche pharmaceutical business AMCo has opened an office in Dubai to make more of its medicines available to doctors, hospitals and healthcare professionals in the Middle East.
Sanofi has taken on Pfizer/Bayer veteran Olivier Brandicourt as it's CEO - with, according to reports, a ‘golden handshake’ worth about $4.5 million. The French government calls this 'incomprehensible' - but one pharma boss disagrees.
It’s good to keep on top of industry trends and the pharma sector is no exception. Lu Rahman looks at some of the key trends likely to feature significantly in 2015
Stephen Archer of Spring Partnerships looks back on months of M&A buzz in the pharma community, and examines whether the industry really stands to benefit from corporate buyouts.
The pharmaceutical manufacturers’ specialism in drug development, manufacturing and packaging services will complement PCI’s growth in clinical trial and commercial supply services in both North America and Europe.
The facility will be spread over 100,000 sq. ft (around 15 acre plot) and the company will first begin work on an oral solid unit and thereafter set up manufacturing units for injectables and topicals.
As we waited to see whether or not Pfizer would be successful in its takeover of AstraZeneca, the approach has raised several issues for the pharmaceutical sector, says Lu Rahman.
